Bay­er on job cuts, pipeline gaps, obe­si­ty and Mon­san­to lit­i­ga­tion as ex­ecs de­fend keep­ing cur­rent struc­ture

Bay­er’s top ex­ecs have their work cut out for them over the next two to three years, as the com­pa­ny holds on­to its con­glom­er­ate struc­ture to hun­ker down and fix the bro­ken parts across its phar­ma, con­sumer health and crop sci­ence units. They al­so have lots of ques­tions to an­swer.

Flanked by his board of man­age­ment on bar stools and don­ning his sig­na­ture black jack­et and T-shirt on a me­dia call, CEO Bill An­der­son of­fered a pas­sion­ate de­fense for the de­ci­sion not to break up the com­pa­ny now, fea­tur­ing a per­son­al sto­ry about a bro­ken fe­mur.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER